

Middle East & Africa Human Vaccine Market Research Report Information by Vaccine Type (Inactivated, Toxoid, Conjugate and Subunit, Recombinant DNA), by Age Group (Pediatrics, and Adults), by Indication (Pneumococcal, Influenza, Hepatitis, DTP, Polio and others), by Route of Administration (Injectable, Oral, and others), by Distribution Channel (Public, and Private) Forecast to 2032

Market Report | 2025-02-14 | 174 pages | Market Research Future

AVAILABLE LICENSES:

- Single User Price \$2950.00
- Enterprisewide Price \$5250.00

Report description:

Middle East & Africa Human Vaccine Market Research Report Information by Vaccine Type (Inactivated, Toxoid, Conjugate and Subunit, Recombinant DNA), by Age Group (Pediatrics, and Adults), by Indication (Pneumococcal, Influenza, Hepatitis, DTP, Polio and others), by Route of Administration (Injectable, Oral, and others), by Distribution Channel (Public, and Private) Forecast to 2032

Overview of the Market

During the review period, the human vaccine market in the Middle East and Africa is expected to grow at a compound annual growth rate (CAGR) of 8.80%. Human vaccinations are biological preparations that protect people from illness and its potentially serious effects by inducing immunity to a particular disease in the immune system. To elicit an immune response without actually causing the disease, these vaccines usually contain pathogens (such bacteria or viruses), their toxins, or surface proteins that have been weakened or destroyed.

The market for human vaccines in the Middle East and Africa is expanding due to rising disease burden, epidemic outbreaks, and growing knowledge of the value of vaccination in avoiding infectious illnesses. Furthermore, the industry will have future growth prospects due to the growing finance and investment for expansion.

Market Segment Insights

The human vaccination market in the Middle East and Africa has been divided into four segments based on the kind of vaccine:

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

inactivated, toxoid, conjugate and subunit, and recombinant DNA.

The human vaccine market in the Middle East and Africa has been divided into two age groups: adults and pediatrics. Throughout the projected period, the pediatrics sector grew at the highest rate and held the largest market in 2023.

The human vaccine market in the Middle East and Africa has been divided into segments based on indications, including polio, DTP, hepatitis, influenza, and pneumococcal.

The human vaccine market in the Middle East and Africa has been divided into injectable, oral, and other segments based on the route of administration.

The human vaccine market in the Middle East and Africa has been divided into two segments based on the distribution channel: public and private.

The market for human vaccines in the Middle East, which is further divided into the United Arab Emirates, Saudi Arabia, Israel, Kuwait, Oman, Qatar, Egypt, Bahrain, and the Rest of the Middle East, was worth USD Egypt million in 2023.

The market for human vaccines in the Middle East is expected to increase significantly due to rising healthcare costs, growing government backing for the vaccine, and growing awareness of its significance. The Kingdom of Saudi Arabia committed to funding the Global Polio Eradication Initiative (GPEI) with \$500 million over five years in April 2024. The launch of novel vaccinations that target a wider variety of diseases and improvements in vaccine technology further support the market's growth. To fight newly developing infectious diseases, current trends point to a move toward customized vaccinations and higher spending on research and development.

Key Players

Pfizer Inc., Merck & Co., Inc., AstraZeneca, Bharat Biotech, SaudiVax, Biovac, Vacsera, Cipla, GSK Plc, and Sanofi are the major companies in the Middle East human vaccine market.

Table of Contents:

TABLE OF CONTENTS

1EXECUTIVE SUMMARY 20

2MARKET INTRODUCTION22

2.1DEFINITION22

2.2SCOPE OF THE STUDY22

2.3RESEARCH OBJECTIVE22

2.4MARKET STRUCTURE23

3RESEARCH METHODOLOGY24

3.1OVERVIEW24

3.2DATA FLOW26

3.2.1DATA MINING PROCESS26

3.3PURCHASED DATABASE:27

3.4SECONDARY SOURCES:28

3.4.1SECONDARY RESEARCH DATA FLOW:29

3.5PRIMARY RESEARCH:30

3.5.1PRIMARY RESEARCH DATA FLOW:31

3.5.2PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED32

3.6APPROACHES FOR MARKET SIZE ESTIMATION:32

3.6.1REVENUE ANALYSIS APPROACH32

3.7DATA FORECASTING33

3.7.1DATA FORECASTING TYPE33

3.8DATA MODELING34

3.8.1MICROECONOMIC FACTOR ANALYSIS:34

3.8.2DATA MODELING:35

3.9	TEAMS AND ANALYST CONTRIBUTION	37
3.10		38
4	MARKET DYNAMICS	39
4.1	INTRODUCTION	39
4.2	DRIVERS	40
4.2.1	INCREASING AWARENESS ABOUT THE IMPORTANCE OF VACCINATION IN PREVENTING INFECTIOUS DISEASES	40
4.2.2	RIISING DISEASE BURDEN AND EPIDEMIC OUTBREAKS	40
4.2.3	RIISING STRATEGIC INITIATIVES ASSOCIATED WITH VACCINE IN MIDDLE EAST & AFRICA	40
4.3	RESTRAINTS	41
4.3.1	STRINGENT REGULATORY POLICIES	41
4.4	OPPORTUNITY	43
4.4.1	INCREASING FUNDING AND INVESTMENT FOR EXPANSION	43
5	MARKET FACTOR ANALYSIS	44
5.1	PORTER'S FIVE FORCES MODEL	44
5.1.1	THREAT OF NEW ENTRANTS	45
5.1.2	BARGAINING POWER OF SUPPLIERS	45
5.1.3	BARGAINING POWER OF BUYERS	45
5.1.4	THREAT OF SUBSTITUTES	45
5.1.5	INTENSITY OF RIVALRY	45
5.2	IMPACT OF COVID-19 ON THE MIDDLE EAST & AFRICA HUMAN VACCINES MARKET	46
6	MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY VACCINE TYPE	48
6.1	OVERVIEW	48
6.2	INACTIVATED	50
6.3	TOXOID	51
6.4	CONJUGATE AND SUBUNIT	51
6.5	RECOMBINANT DNA	51
7	MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY AGE GROUP	52
7.1	OVERVIEW	52
7.2	PEDIATRICS	54
7.3	ADULTS	54
8	MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY INDICATION	55
8.1	OVERVIEW	55
8.2	PNEUMOCOCCAL	58
8.3	INFLUENZA	58
8.4	HEPATITIS	58
8.4.1	HEPATITIS A	59
8.4.2	HEPATITIS B	60
8.5	DTP	60
8.6	POLIO	61
8.6.1	INACTIVATED POLIO VACCINE (IPV)	62
8.6.2	ORAL POLIO VACCINE (OPV)	62
8.7	HUMAN PAPILLOMAVIRUS	62
8.8	MENINGOCOCCAL	63
9	MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION	64
9.1	OVERVIEW	64
9.2	INJECTABLE	67
9.3	ORAL	67

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

9.4	OTHERS	67
10	MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL	68
10.1	OVERVIEW	68
10.2	PUBLIC	70
10.3	PRIVATE	70
11	MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY REGION	71
11.1	MIDDLE EAST	72
11.1.1	UAE	79
11.1.2	SAUDI ARABIA	83
11.1.3	ISRAEL	87
11.1.4	KUWAIT	91
11.1.5	OMAN	96
11.1.6	QATAR	99
11.1.7	EGYPT	102
11.1.8	BAHRAIN	106
11.1.9	REST OF MIDDLE EAST	109
11.2	AFRICA	113
11.2.1	KENYA	119
11.2.2	SOUTH AFRICA	122
11.2.3	NIGERIA	126
11.2.4	MOZAMBIQUE	129
11.2.5	TANZANIA	132
11.2.6	UGANDA	136
11.2.7	MOROCCO	139
11.2.8	REST OF AFRICA	143
12	COMPETITIVE LANDSCAPE	148
12.1	INTRODUCTION	148
12.2	MARKET SHARE ANALYSIS, 2023 (%)	148
12.3	COMPETITOR DASHBOARD	149
12.4	PUBLIC PLAYERS STOCK SUMMARY	150
12.5	COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL	150
12.6	KEY DEVELOPMENTS & GROWTH STRATEGIES	151
12.6.1	PRODUCT LAUNCH/PRODUCT APPROVAL	151
12.6.2	AGREEMENT/COLLABORATION/PARTNERSHIP	151
13	COMPANY PROFILES	152
13.1	SANOFI	152
13.1.1	COMPANY OVERVIEW	152
13.1.2	FINANCIAL OVERVIEW	153
13.1.3	PRODUCTS OFFERED	153
13.1.4	KEY DEVELOPMENTS	154
13.1.5	SWOT ANALYSIS	155
13.1.6	KEY STRATEGIES	155
13.2	BHARAT BIOTECH	156
13.2.1	COMPANY OVERVIEW	156
13.2.2	FINANCIAL OVERVIEW	157
13.2.3	PRODUCTS OFFERED	157
13.2.4	KEY DEVELOPMENTS	157

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

13.2.5	KEY STRATEGIES	157
13.3	PFIZER INC	158
13.3.1	COMPANY OVERVIEW	158
13.3.2	FINANCIAL OVERVIEW	159
13.3.3	PRODUCTS OFFERED	159
13.3.4	KEY DEVELOPMENTS	160
13.3.5	SWOT ANALYSIS	160
13.3.6	KEY STRATEGIES	161
13.4	MERCK & CO., INC.	162
13.4.1	COMPANY OVERVIEW	162
13.4.2	FINANCIAL OVERVIEW	163
13.4.3	PRODUCTS OFFERED	164
13.4.4	KEY DEVELOPMENTS	164
13.4.5	KEY STRATEGIES	164
13.5	ASTRAZENECA	165
13.5.1	COMPANY OVERVIEW	165
13.5.2	FINANCIAL OVERVIEW	166
13.5.3	PRODUCTS OFFERED	166
13.5.4	KEY DEVELOPMENTS	167
13.5.5	KEY STRATEGIES	167
13.6	CIPLA	168
13.6.1	COMPANY OVERVIEW	168
13.6.2	FINANCIAL OVERVIEW	169
13.6.3	PRODUCTS OFFERED	169
13.6.4	KEY DEVELOPMENTS	169
13.6.5	SWOT ANALYSIS	170
13.6.6	KEY STRATEGIES	170
13.7	SAUDIVAX	171
13.7.1	COMPANY OVERVIEW	171
13.7.2	FINANCIAL OVERVIEW	172
13.7.3	PRODUCTS OFFERED	172
13.7.4	KEY DEVELOPMENTS	172
13.7.5	KEY STRATEGIES	172
13.8	GSK PLC	173
13.8.1	COMPANY OVERVIEW	173
13.8.2	FINANCIAL OVERVIEW	174
13.8.3	PRODUCT OFFERED	175
13.8.4	KEY DEVELOPMENTS	175
13.8.5	SWOT ANALYSIS	176
13.8.6	KEY STRATEGIES	176
13.9	BIOVAC	177
13.9.1	COMPANY OVERVIEW	177
13.9.2	FINANCIAL OVERVIEW	178
13.9.3	PRODUCTS OFFERED	178
13.9.4	KEY DEVELOPMENTS	178
13.9.5	KEY STRATEGIES	178
13.10	VACSERA	179

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

13.10.1	COMPANY OVERVIEW	179
13.10.2	FINANCIAL OVERVIEW	179
13.10.3	PRODUCTS OFFERED	179
13.10.4	KEY DEVELOPMENTS	180
13.10.5	KEY STRATEGIES	180
14	DATA CITATIONS	181

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Middle East & Africa Human Vaccine Market Research Report Information by Vaccine Type (Inactivated, Toxoid, Conjugate and Subunit, Recombinant DNA), by Age Group (Pediatrics, and Adults), by Indication (Pneumococcal, Influenza, Hepatitis, DTP, Polio and others), by Route of Administration (Injectable, Oral, and others), by Distribution Channel (Public, and Private) Forecast to 2032

Market Report | 2025-02-14 | 174 pages | Market Research Future

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User Price	\$2950.00
	Enterprisewide Price	\$5250.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Date

2025-05-13

Signature



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com